# Safety, Tolerability, and Immunogenicity of Recombinant Meningococcal Group B Vaccine (E.Coli)

> **NCT06314880** · PHASE1 · UNKNOWN · sponsor: **Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd** · enrollment: 300 (estimated)

## Conditions studied

- Healthy Volunteers

## Interventions

- **BIOLOGICAL:** Recombinant Meningococcal Group B Vaccine (E. Coli) (low-dose)
- **BIOLOGICAL:** Recombinant Meningococcal Group B Vaccine (E. Coli) (hign-dose)
- **BIOLOGICAL:** Placebo control

## Key facts

- **NCT ID:** NCT06314880
- **Lead sponsor:** Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-07-22
- **Primary completion:** 2024-12-30
- **Final completion:** 2024-12-30
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2024-04-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06314880

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06314880, "Safety, Tolerability, and Immunogenicity of Recombinant Meningococcal Group B Vaccine (E.Coli)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06314880. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*